Avastin and Lucentis 'both effective for treating wet AMD'

8 May 2012

An unlicensed drug which could treat wet age-related macular degeneration (AMD) for a cheaper price has been found to be just as effective as the most popular treatment.

Results of a major study involving hundreds of eye patients could pave the way for Avastin replacing Lucentis when it comes to treating this common cause of blindness.

According to the study, which has been titled IVAN, there is no functional difference in the effects of each drug, while their impact on reducing vision loss was also almost undistinguishable.

However, the research goes on to suggest that by switching from Lucentis to Avastin, the NHS could save £84.5 million a year, on the basis that 17,295 eyes are treated annually.

Andrew Lotery, a professor of ophthalmology at the University of Southampton and consultant ophthalmologist at Southampton General Hospital, stated: "Avastin is a much cheaper drug and as such if the NHS switched to Avastin cost savings of many millions of pounds would result."

Wet AMD affects around ten per cent of patients with AMD, with some of the early symptoms being that straight lines appear wavy and a blind spot developing in the eye.

Posted by Jeanette Royston

Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)